Abstract
Multiple sclerosis is an autoimmune disease with inflammatory lesions localized to the white matter of the central nervous system. Early on, the disease is characterized by episodes of exacerbations and remissions. During exacerbations there is an acute inflammatory infiltrate characterized by the presence of mononuclear cells, monocytes, and T lymphocytes. These cells produce proinflammatory cytokines that have been implicated in the amplification of the inflammatory response as well as in the damage of oligodendrocytes. The inflammation ultimately results in loss of myelin and oligodendrocyte cell death (demyelination). Thus therapies aimed at preventing the inflammatory response may have a beneficial effect on the course of the disease. One such therapy is treatment with inhibitors of phosphodiesterase type IV. These drugs have proven to be extremely effective in the prevention and treatment of experimental allergic encephalomyelitis, the animal model for multiple sclerosis. These experiments, as well as other data discussed here, provide a rationale for the treatment of multiple sclerosis with inhibitors of phosphodiesterase type IV.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 6 June 1996 / Accepted: 3 September 1996
Rights and permissions
About this article
Cite this article
Dinter, H., Onuffer, J., Faulds, D. et al. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med 75, 95–102 (1997). https://doi.org/10.1007/s001090050094
Issue Date:
DOI: https://doi.org/10.1007/s001090050094